Patents by Inventor Frederic Dargelas
Frederic Dargelas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230119355Abstract: The present invention relates to pharmaceutical compositions comprising hydrochloride salt of N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (I) as an active ingredient and copovidone as an excipient. Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.Type: ApplicationFiled: March 5, 2021Publication date: April 20, 2023Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Frederic DARGELAS, Piritta KOISTINEN, Laura LEIMU, Laura MATILAINEN, Henri METSALA, Anna SHEVCHENKO
-
Publication number: 20160338966Abstract: The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium. The form comprises an agent D, which is a pharmaceutically acceptable compound whose hydration or solvation rate or capacity is greater in an alcohol-free aqueous medium than in alcoholic solution.Type: ApplicationFiled: April 19, 2016Publication date: November 24, 2016Inventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20150313846Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.Type: ApplicationFiled: April 28, 2015Publication date: November 5, 2015Inventors: Florence Guimberteau, Frederic Dargelas
-
Patent number: 9023400Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.Type: GrantFiled: May 24, 2007Date of Patent: May 5, 2015Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Patent number: 8895063Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.Type: GrantFiled: January 10, 2007Date of Patent: November 25, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas, Gérard Soula, Rémi Soula
-
Publication number: 20140072644Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: FLAMEL TECHNOLOGIESInventors: Florence Guimberteau, Frederic Dargelas
-
Patent number: 8652529Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle they contain. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the active principle it comprises is contained in coated microparticles for modified release of the active principle, and in that the coated microparticles have a coating layer which assures modified release of the active principle and simultaneously imparts crushing resistance to the coated microparticles so as to avoid misuse.Type: GrantFiled: May 24, 2006Date of Patent: February 18, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frédéric Dargelas
-
Patent number: 8445023Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: GrantFiled: December 15, 2009Date of Patent: May 21, 2013Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20110275693Abstract: The present invention relates to an immediate release formulation of pharmaceutical compounds.Type: ApplicationFiled: January 27, 2010Publication date: November 10, 2011Applicant: UCB PHARMA, S.A.Inventors: Serge Cuypers, Monique Berwaer, Domenico Fanara, Valery Barillaro, Martine Larbanoix, Frederic Dargelas
-
Publication number: 20110104266Abstract: The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium. The form comprises an agent 13, which is a pharmaceutically acceptable compound whose hydration or solvation rate or capacity is greater in an alcohol-free aqueous medium than in alcoholic solution.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: Flamel TechnologiesInventors: Florence Guimberteau, Frédéric Dargelas
-
Publication number: 20100092553Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: ApplicationFiled: December 15, 2009Publication date: April 15, 2010Applicant: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20090220611Abstract: The invention concerns microparticulate systems with modified release of oral active principle(s). The invention aims at providing a novel pharmaceutical with time-dependent and pH-dependent release mechanism, enabling: a) the latent period preceding the release of the active principle in the stomach; b) the pH triggering the release of the active principle in the intestine; c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. A comprises: film-forming (co)polymer (A1) insoluble in fluids of the gastrointestinal tract; ethylcellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract; plasticizing polyvinylpyrrolidone (A3); castor oil/optionally a surfactant and/or magnesium stearate lubricant (A4). B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (EUDRAGIT® L100-55) and a hydrophobic compound (B2) (LUBRITAB®).Type: ApplicationFiled: September 27, 2006Publication date: September 3, 2009Inventors: Frederic Dargelas, Florence Guimberteau, Catherine Castan, Remi Meyrueix, Gerard Soula
-
Publication number: 20080193540Abstract: The invention relates to the field of solid medicaments that are intended for the oral administration of active ingredients. The aim of the invention is to prevent the improper use of solid, oral medicaments for any user other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characturised in that it comprises: A) at least one caking agent; and B) at least one viscosifying agent, such as to prevent the misuse thereof.Type: ApplicationFiled: November 21, 2005Publication date: August 14, 2008Applicant: Flamel TechnologiesInventors: Gerard Soula, Frederic Dargelas
-
Publication number: 20080063725Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.Type: ApplicationFiled: May 24, 2007Publication date: March 13, 2008Applicant: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20080008659Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.Type: ApplicationFiled: January 10, 2007Publication date: January 10, 2008Applicant: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas, Gerard Soula, Remi Soula
-
Publication number: 20070264346Abstract: The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium.Type: ApplicationFiled: February 16, 2007Publication date: November 15, 2007Applicant: Flamel TechnologiesInventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20070224129Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: ApplicationFiled: May 24, 2006Publication date: September 27, 2007Applicant: Flamel Technologies, Inc.Inventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20070202049Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.Type: ApplicationFiled: May 24, 2006Publication date: August 30, 2007Applicant: Flamel Technologies, Inc.Inventors: Florence Guimberteau, Frederic Dargelas, Gerard Soula, Remi Soula